A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Overweight and Obesity

Interventions

DRUG

DA-302168S

A small molecule GLP-1R agonist tablet, orally administration, once daily，16weeks.

DRUG

Placebo of DA-302168S

Matching placebo tablet will be provided

Trial Locations (1)

Peking University People's Hospital, Beijing